Yoshitaka Kikukawa

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands (<scp>PD</scp>‐L1/2) on infiltrating macrophages in lymphoma

Hasita Horlad, Chaoya Ma, Hiromu Yano et al. · Cancer Science · 2016 · 134 citations · Full text

Life Sciences, Immunology, Oncology +17

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells

Naoko Wada, Yawara Kawano, Shiho Fujiwara et al. · International Journal of Oncology · 2014 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1

Shiho Fujiwara, Naoko Wada, Yawara Kawano et al. · Experimental Hematology and Oncology · 2015 · 56 citations · Full text

Medicine, Cancer Biology, Oncology +15

Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus

Keiko Ono, Hitoshi Suzushima, Yuko Watanabe et al. · Internal Medicine · 2012 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17